Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Clasificación en acciones #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Precio por acción
$0.03702159
Última sincronización: 2024-01-29
Capitalización bursátil
$7.21M
Cambio (1 día)
-3.08%
Cambio (1 año)
0.00%
País
AU
Comercio Antisense Therapeutics Limited (ANP)

Categoría

Historial de desdoblamientos de acciones de Antisense Therapeutics Limited (ANP)
La acción Antisense Therapeutics Limited (símbolo: ANP) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 17, 2026.
Una acción ANP comprada antes de Aug 17, 2026 equivaldría hoy a 0 acciones ANP.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
0 -
DE
0 -
DE
0 -
JP
0 -
CH
5 x119
IN